- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NEONC TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 27.07. | NeOnc beruft Nasim Shomali in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 27.07. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors | 189 | GlobeNewswire (Europe) | CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| 15.07. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.07. | NeOnc Technologies Holdings, Inc.: NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition | 1 | GlobeNewswire (USA) | ||
| 02.07. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 18 | SEC Filings | ||
| 24.06. | 24/7 Market News and NeOnc Technology: NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum | 1 | GlobeNewswire (USA) | ||
| 23.06. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.06. | NeOnc receives UAE approval for NEO100 glioma drug trials | 1 | Investing.com | ||
| 23.06. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone | 264 | GlobeNewswire (Europe) | Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S. development, where... ► Artikel lesen | |
| 22.06. | WallStreet-PR: WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy | 369 | Newsfile | Houston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) recently achieved what many biotechnology companies spend years attempting to secure: international... ► Artikel lesen | |
| 16.06. | 24/7 Market News and NeOnc Technology: Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND | 1 | GlobeNewswire (USA) | ||
| 16.06. | NeOnc Technologies Holdings, Inc.: NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development | 1 | GlobeNewswire (USA) | ||
| 15.06. | WallStreet-PR: WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates | 308 | Newsfile | Houston, Texas--(Newsfile Corp. - June 15, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) continues to attract attention within the biotechnology sector as the Company advances its neuro-oncology... ► Artikel lesen | |
| 12.06. | NeOnc Technologies secures $5M private placement via Series A preferred stock | 12 | Seeking Alpha | ||
| 12.06. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.05. | 24/7 Market News and NeOnc Technology: The Next Great AI Revolution May Be Drug Delivery | 3 | GlobeNewswire (USA) | ||
| 19.05. | 24/7 Market News and NeOnc Technology: NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones | 1 | GlobeNewswire (USA) | ||
| 18.05. | NEONC TECHNOLOGIES HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | NeOnc Technologies Holdings GAAP EPS of -$0.38 | 3 | Seeking Alpha | ||
| 18.05. | NeOnc Technologies Holdings, Inc.: NeOnc Provides Business Update and Reports Q1 2026 Financial Results | 957 | GlobeNewswire (Europe) | CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company advancing two Phase 2 programs... ► Artikel lesen |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 7,770 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,094 | -0,91 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,281 | +2,18 % | Der Weg zur Klinik: Wie Finanzierung Biotech-Erfolge ermöglicht | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,021 | -0,39 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,595 | +0,83 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| ONCO-INNOVATIONS | 0,400 | -0,99 % | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| NOVOCURE | 13,700 | -3,32 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,700 | -3,14 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,140 | +0,32 % | Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial | ||
| PALISADE BIO | 2,110 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis | ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,803 | 0,00 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial | Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 0,886 | -0,11 % | XFRA 41O: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| REGENXBIO | 9,000 | -2,93 % | REGENXBIO Inc.: REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights | RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027
Long-term surabgene lomparvovec... ► Artikel lesen | |
| OMEROS | 11,200 | -2,18 % | Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA | Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing... ► Artikel lesen |
NEONC TECHNOLOGIES HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,490 Euro und damit -0,29 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEONC TECHNOLOGIES HOLDINGS INC finden Sie auf Wallstreet Online.